Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Nguyen, Huu Phuc ^a   Hübener, Jeannette ^a   Weber, Jonasz Jeremiasz ^a   Grueninger, Stephan ^b   Riess, Olaf ^a   Weiss, Andreas ^b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; BRAIN PROTEIN; MUTANT PROTEIN; MJD PROTEIN, MOUSE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CEREBELLUM; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; HOMEOSTASIS; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOASSAY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR DEGENERATION; TRANSGENIC MOUSE; AGE; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; DISEASE MODEL; FLUOROIMMUNOASSAY; GENE EXPRESSION; GENETICS; MACHADO JOSEPH DISEASE; METABOLISM; MOLECULAR GENETICS; MUTATION; PROCEDURES; PURKINJE CELL; TRANSGENE;

MUS;

AGE FACTORS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CEREBELLUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUOROIMMUNOASSAY; GENE EXPRESSION; HUMANS; MACHADO-JOSEPH DISEASE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PURKINJE CELLS; TRANSCRIPTION FACTORS; TRANSGENES;

EID: 84876556068     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062043     Document Type: Article

References (32)

1. Riess O, Rüb U, Pastore A, Bauer P, Schöls L, (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7: 125-137.
2. Michalik A, Van Broeckhoven C, (2003) Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 12 Spec No 2: R173-86.
3. Williams AJ, Paulson HL, (2008) Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 31: 521-528.
4. Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, et al. (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 24: 10266-10279.
5. Koch P, Breuer P, Peitz M, Jungverdorben J, Kesavan J, et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 480: 543-546.
6. Hübener J, Weber JJ, Richter C, Honold L, Weiss A, et al. (2013) Calpain mediated ataxin-3 cleavage in the molecular pathogenesis of Spinocerebellar Ataxia Type 3 (SCA3). Hum Mol Genet 22: 508-518.
7. Simoes AT, Goncalves N, Koeppen A, Deglon N, Kügler S, et al. (2012) Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin-3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 135: 2428-2439.
8. Bertram L, Hampel H, (2011) The role of genetics for biomarker development in neurodegeneration. Prog Neurobiol 95: 501-504.
9. Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, et al. (2012) TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntingtońs disease. Chem Biol 19: 264-275.
10. Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, et al. (2009) Single- step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntingtońs disease. Anal Biochem 395: 8-15.
11. Ran C, Zhao W, Moir RD, Moore A, (2011) Non-conjugated small molecule FRET for differentiating monomers from high molecular weight amyloid beta species. PLoS One 6: e19362.
12. Kaminski Schierle GS, Bertoncini CW, Chan FTS, van der Goot AT, Schwendler S, et al. (2011) A FRET Sensor for non-invasive imaging of amyloid formation in vivo. Chem Phys Chem 12: 673-680.
13. Bidinosti M, Shimshek DR, Mollenbauer B, Marcellin D, Schweizer T, et al. (2012) Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem 287: 33691-33705.
14. Cottet M, Faklaris O, Maurel D, Scholler P, Doumazane E, et al. (2012) BRET and time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues. Front Endocrinol (Lausanne) 3: 92.
15. Ko J, Ou S, Patterson PH, (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 56: 319-329.
16. Bichelmeier U, Schmidt T, Hübener J, Boy J, Rüttiger L, et al. (2007) Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 27: 7418-7428.
17. Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, et al. (2008) Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntingtońs disease. J Neurochem 104: 846-858.
18. Maruyama H, Nakamura S, Matsuyama Z, Sakai T, Doyu M, et al. (1995) Molecular features of the CAG repeats and clinical manifestation of Machado- Joseph disease. Hum Mol Genet 4: 807-812.
19. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506.
20. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, et al. (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of Spinocerebellar ataxia type 3. Brain 133: 93-104.
21. Seidel K, Siswanto S, Brunt ERP, den Dunnen W, Korf HW, et al. (2012) Brain pathology of spinocerebellar ataxias. Acta Neuropathol 124 1-21: 22.
22. Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, et al. (2012) Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res 229: 308-319.
23. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158-9167.
24. Kim J, Yi Y, Sapp E, Wang Y, Cuiffo B, et al. (2001) Caspase 3-cleaved N- terminal fragments of wildtype and mutant huntingtin are present in normal and Huntington's disease brains, associated with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A 98: 12784-12789.
25. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, et al. (2004) Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11: 424-438.
26. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179-1191.
27. Gafni J, Ellerby LM, (2002) Calpain activation in Huntington's disease. J Neurosci 22: 4842-4849.
28. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, et al. (2004) Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem 279: 20211-20220.
29. Berke S, Schmied FA, Brunt ER, Ellerby LM, Paulson HL, (2004) Caspase- mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 89: 908-918.
30. Pozzi C, Valtorta M, Tedeschi G, Galbusera E, Pastori V, et al. (2008) Study of subcellular localization and proteolysis of ataxin-3. Neurobiol Dis 30: 190-200.
31. Jung J, Xu K, Lessing D, Bonini NM, (2009) Preventing ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 18: 4843-4852.
32. Haacke A, Hartl FU, Breuer P, (2007) Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J Biol Chem 26: 18851-18856.